0001144204-19-013284.txt : 20190311 0001144204-19-013284.hdr.sgml : 20190311 20190311160222 ACCESSION NUMBER: 0001144204-19-013284 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190309 FILED AS OF DATE: 20190311 DATE AS OF CHANGE: 20190311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bernhardt Charles Thomas III CENTRAL INDEX KEY: 0001458282 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36598 FILM NUMBER: 19672290 MAIL ADDRESS: STREET 1: 23 BIRCH ROAD CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cellectar Biosciences, Inc. CENTRAL INDEX KEY: 0001279704 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043321804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (608) 441-8120 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: NOVELOS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20050617 FORMER COMPANY: FORMER CONFORMED NAME: COMMON HORIZONS INC DATE OF NAME CHANGE: 20040211 3 1 tv515884_3.xml OWNERSHIP DOCUMENT X0206 3 2019-03-09 1 0001279704 Cellectar Biosciences, Inc. CLRB 0001458282 Bernhardt Charles Thomas III C/O CELLECTAR BIOSCIENCE, INC. 100 CAMPUS DRIVE FLORHAM NJ 07932 0 1 0 0 Interim CFO Exhibit 24 - Power of Attorney /s/ Christine Blakely, Attorney-in-fact for Charles T. Bernhardt 2019-03-11 EX-24 2 tv515884_ex24.htm EXHIBIT 24

Exhibit 24

 

 

CONFIRMING STATEMENT

 

This Statement confirms that the undersigned has authorized and designated Gregory J. Lynch, Joshua B. Erekson, Stacy Fredericks, Charles T. Bernhardt and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The authority of Gregory J. Lynch, Joshua B. Erekson, Stacy Fredericks, Charles T. Bernhardt and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned’s ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Gregory J. Lynch, Joshua B. Erekson, Stacy Fredericks, Charles T. Bernhardt and Christina Blakley are not assuming any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

 

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned’s filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

 

Dated: March 6, 2019 Signed:  /s/ Charles T. Bernhardt               
   
  Print Name:  Charles Thomas Bernhardt III